Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación
Artículo científico (JournalArticle)
Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
Intravitreal administration of anti-vascular endothelial growth factor (VEGF) antibodies
has become the standard treatment for Age-Related Macular Degeneration; however, the knowledge
of their pharmacokinetics is limited. A comprehensive review of the preclinical and clinical
pharmacokinetic data that were obtained in different studies with intravitreal bevacizumab,
ranibizumab, and aflibercept has been conducted. Moreover, the factors that can influence the
vitreous pharmacokinetics of these drugs, as well as the methods that were used in the studies
for analytical determination, have been exposed. These anti-VEGF drugs present different charge
and molecular weights, which play an important role in vitreous distribution and elimination.
The pharmacokinetic parameters that were collected differ depending on the species that were
involved in the studies and on physiological and pathological conditions, such as vitrectomy and
lensectomy. Knowledge of the intravitreal pharmacokinetics of the anti-VEGF drugs that were used
in clinical practice is of vital importance.